- Home
- HUBG vs AKRO Comparison
HUBG vs AKRO Comparison
Compare HUBG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBG
- AKRO
- Stock Information
- Founded
- HUBG 1971
- AKRO 2017
- Country
- HUBG United States
- AKRO United States
- Employees
- HUBG N/A
- AKRO N/A
- Industry
- HUBG Oil Refining/Marketing
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HUBG Consumer Discretionary
- AKRO Health Care
- Exchange
- HUBG Nasdaq
- AKRO Nasdaq
- Market Cap
- HUBG 2.7B
- AKRO 2.4B
- IPO Year
- HUBG 1996
- AKRO 2019
- Fundamental
- Price
- HUBG $49.66
- AKRO $28.09
- Analyst Decision
- HUBG Buy
- AKRO Strong Buy
- Analyst Count
- HUBG 12
- AKRO 7
- Target Price
- HUBG $46.83
- AKRO $43.20
- AVG Volume (30 Days)
- HUBG 485.2K
- AKRO 617.2K
- Earning Date
- HUBG 10-30-2024
- AKRO 11-08-2024
- Dividend Yield
- HUBG 1.01%
- AKRO N/A
- EPS Growth
- HUBG N/A
- AKRO N/A
- EPS
- HUBG 1.77
- AKRO N/A
- Revenue
- HUBG $3,957,903,000.00
- AKRO N/A
- Revenue This Year
- HUBG N/A
- AKRO N/A
- Revenue Next Year
- HUBG $6.67
- AKRO N/A
- P/E Ratio
- HUBG $28.14
- AKRO N/A
- Revenue Growth
- HUBG N/A
- AKRO N/A
- 52 Week Low
- HUBG $36.89
- AKRO $14.41
- 52 Week High
- HUBG $50.83
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- HUBG 66.51
- AKRO 38.58
- Support Level
- HUBG $48.79
- AKRO $31.12
- Resistance Level
- HUBG $50.20
- AKRO $35.11
- Average True Range (ATR)
- HUBG 1.68
- AKRO 1.99
- MACD
- HUBG 0.54
- AKRO -0.53
- Stochastic Oscillator
- HUBG 90.77
- AKRO 11.68
About HUBG Hub Group Inc.
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset light truck brokerage operations, along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub is somewhat acquisitive in that it often makes tuck-in acquisitions which expand its brokerage, last-mile, and dedicated offerings.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.